Status and phase
Conditions
Treatments
About
This prospective, open-label, single-arm, multicenter study will evaluate the efficacy and safety of arsenic trioxide (ATO) combined with chemotherapy in pediatric patients with relapsed or refractory SHH-activated medulloblastoma and/or TP53-mutant medulloblastoma. Eligible participants will be 18 months to 18 years of age.
Participants will receive six cycles of induction chemotherapy containing ATO in combination with etoposide and either cisplatin or cyclophosphamide. The primary outcome is the objective response rate (ORR), defined as the proportion of participants achieving a complete response or partial response, assessed according to the Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria by an independent review committee.
Secondary outcomes include overall survival, progression-free survival, and treatment-related safety, including adverse events and serious adverse events. A total of 78 participants are planned for enrollment.
Full description
Medulloblastoma is a malignant pediatric central nervous system tumor. Patients with relapsed or refractory disease, particularly those with SHH-activated tumors and/or TP53 mutations, have limited treatment options and generally poor outcomes. Arsenic trioxide (ATO) has demonstrated antitumor activity through mechanisms involving inhibition of the SHH signaling pathway and restoration of the function of selected mutant TP53 proteins.
This is a prospective, open-label, single-arm, multicenter clinical study designed to investigate the efficacy and safety of ATO combined with chemotherapy in pediatric patients with relapsed or refractory SHH-activated medulloblastoma and/or TP53-mutant medulloblastoma.
Induction treatment consists of six 21-day cycles. Cycles 1, 3, and 5 include ATO, etoposide, and cisplatin, while cycles 2, 4, and 6 include ATO, etoposide, and cyclophosphamide. Intrathecal methotrexate with dexamethasone may also be administered according to the study protocol. Following induction therapy, subsequent consolidation or maintenance treatment may be selected according to the participant's clinical condition and treatment plan.
Tumor response will be assessed according to RAPNO criteria. The primary efficacy endpoint is objective response rate after completion of induction therapy. Overall survival, progression-free survival, adverse events, and serious adverse events will also be evaluated during treatment and follow-up.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
78 participants in 1 patient group
Loading...
Central trial contact
Yang Li, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal